Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial
Peter Barrett‐Lee(Velindre Cancer Centre), Nick Murray(Royal Adelaide Hospital), Duncan Wheatley(National Health Service), Hayley Timmins(Cardiff University), Kerenza Hood(NHS Digital), Peter Simmonds(University of Turku), Gareth Griffiths(NIHR Evaluation Trials and Studies Coordinating Centre), Robert Grieve, Jacinta Abraham(Velindre NHS Trust), Robert E. Coleman(University of Sheffield), Angela Casbard(Medical Research Council)
Cited by 128
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Consensus Proposals for a Unified System of Nomenclature of Hepatitis C Virus Genotypes *
|Hepatology|2005|1.5k
Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
|Journal of General Virology|1993|1.4k